For instance, in non-small cell lung cancer, Erastin and Sorafenib, either alone or in combination, induce ferroptosis by inhibiting the Nrf2/SLC7A11 (also known as xCT) pathway, thereby overcoming DDP resistance[30]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.